Research graph
References from Dapagliflozin Prevents Heart Failure With Preserved Ejection Fraction by Inhibiting the Sodium/Hydrogen Exchanger. Local targets link to admitted publications; unresolved targets remain external evidence.
HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the heart failure Society of America
10.1016/j.cardfail.2024.07.001 · 2025 · External reference
2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association
10.1161/cir.0000000000001209 · 2024 · External reference
Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum
10.1161/circulationaha.110.954388 · 2011 · External reference
Pathophysiology of systolic and diastolic heart failure
10.1016/j.mcna.2012.07.001 · 2012 · External reference
Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction
10.1080/14779072.2018.1497485 · 2018 · External reference
Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction
10.1161/circulationaha.111.066423 · 2012 · External reference
Trends in prevalence and outcome of heart failure with preserved ejection fraction
10.1056/nejmoa052256 · 2006 · External reference
Progression of left ventricular diastolic dysfunction and risk of heart failure
10.1001/jama.2011.1201 · 2011 · External reference
Progression of left ventricular diastolic dysfunction in ethnic minorities
10.1007/s40292-013-0031-2 · 2014 · External reference
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial
10.1016/s0140-6736(03)14285-7 · 2003 · External reference
Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry
10.1016/j.jacc.2007.04.064 · 2007 · External reference
Empagliflozin in heart failure with a preserved ejection fraction
10.1056/nejmoa2107038 · 2021 · External reference
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
10.1056/nejmoa2206286 · 2022 · External reference
Semaglutide in patients with heart failure with preserved ejection fraction and obesity
10.1056/nejmoa2306963 · 2023 · External reference
10.1161/circulationaha.107.188965
10.1161/circulationaha.107.188965 · 2008 · External reference
Diastolic heart failure: mechanisms and controversies
10.1038/ncpcardio1245 · 2008 · External reference
Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure
10.1038/s41598-025-93144-9 · 2025 · External reference
Expression profiling and immunolocalization of Na(+)-D-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats
10.1007/s00424-017-2056-1 · 2017 · External reference
Beyond adiposity: embracing complexity in diabetes-associated HFpEF
10.1016/j.jacc.2025.08.005 · 2025 · External reference
Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics
10.1093/jmcb/mjac028 · 2022 · External reference
Magnesium supplementation improves diabetic mitochondrial and cardiac diastolic function
10.1172/jci.insight.123182 · 2019 · External reference
Magnesium deficiency causes a reversible, metabolic, diastolic cardiomyopathy
10.1161/jaha.120.020205 · 2021 · External reference
Clinical significance of serum magnesium levels in patients with heart failure with preserved ejection fraction
10.1097/md.0000000000017069 · 2019 · External reference
Inflammatory macrophage interleukin-1β mediates high fat diet induced heart failure with preserved ejection fraction
10.1016/j.jacbts.2022.08.003 · 2023 · External reference
TRPM7 kinase controls cardiac inflammation in a model of heart failure with preserved ejection fraction
2026 · External reference
Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension
10.1152/ajpheart.00903.2007 · 2008 · External reference
Magnesium supplementation attenuates pulmonary hypertension via regulation of magnesium transporters
10.1161/hypertensionaha.120.14909 · 2021 · External reference
Cardiac TRPM7 causes diabetic heart failure with preserved ejection fraction
2025 · External reference
Characterization of the protein kinase activity of TRPM7/ChaK1, a protein kinase fused to the transient receptor potential ion channel
10.1074/jbc.m308820200 · 2004 · External reference
Elucidating the role of the TRPM7 alpha-kinase: TRPM7 kinase inactivation leads to magnesium deprivation resistance phenotype in mice
10.1038/srep07599 · 2014 · External reference
The TRPM7 channel kinase regulates store-operated calcium entry
10.1113/jp274006 · 2017 · External reference
Alteration of the transcriptional profile of human embryonic kidney cells by transient overexpression of mouse TRPM7 channels
10.1159/000327958 · 2011 · External reference
The TRPM7 chanzyme is cleaved to release a chromatin-modifying kinase
10.1016/j.cell.2014.03.046 · 2014 · External reference
TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway
10.1016/j.canlet.2013.01.031 · 2013 · External reference
TRPM7 kinase-mediated immunomodulation in macrophage plays a central role in magnesium ion-induced bone regeneration
10.1038/s41467-021-23005-2 · 2021 · External reference
Ion channel-kinase TRPM7 is required for maintaining cardiac automaticity
10.1073/pnas.1311865110 · 2013 · External reference
Timing of myocardial trpm7 deletion during cardiogenesis variably disrupts adult ventricular function, conduction, and repolarization
10.1161/circulationaha.112.000768 · 2013 · External reference
Comparative effects of sodium-glucose cotransporter 2 inhibitors on serum electrolyte levels in patients with type 2 diabetes: a pairwise and network meta-analysis of randomized controlled trials
10.34067/kid.0006672021 · 2022 · External reference
SGLT2 inhibitors in management of severe hypomagnesemia in patients without diabetes: a report of 4 cases
10.1016/j.xkme.2023.100697 · 2023 · External reference
Empagliflozin ameliorates diabetic cardiomyopathy via attenuating oxidative stress and improving mitochondrial function
2022 · External reference
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
10.1016/j.freeradbiomed.2024.01.015 · 2024 · External reference
Empagliflozin, a sodium-glucose cotransporter inhibitor enhancing mitochondrial action and cardioprotection in metabolic syndrome
10.1002/jcp.31264 · 2024 · External reference
A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
10.1186/s12933-018-0790-0 · 2018 · External reference
Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials
10.1007/s00125-016-4101-6 · 2016 · External reference
Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice
10.1371/journal.pone.0100777 · 2014 · External reference
Magnesium deficiency: effect on bone and mineral metabolism in the mouse
10.1007/s00223-001-1091-1 · 2003 · External reference
The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE(-/-) mice
10.1155/2016/6305735 · 2016 · External reference
Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2
2023 · External reference
Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice
10.1016/j.metabol.2020.154324 · 2020 · External reference
Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells
10.1371/journal.pone.0247234 · 2021 · External reference
Cariporide (HOE642), a selective Na+-H+ exchange inhibitor, inhibits the mitochondrial death pathway
10.1161/01.cir.0000093277.20968.c7 · 2003 · External reference
Rosmarinic acid, as an NHE1 activator, decreases skin surface pH and improves the skin barrier function
10.3390/ijms23073910 · 2022 · External reference
Mitochondrial dysfunction causing cardiac sodium channel downregulation in cardiomyopathy
10.1016/j.yjmcc.2012.10.011 · 2013 · External reference
Circulating S-glutathionylated cMyBP-C as a biomarker for cardiac diastolic dysfunction
10.1161/jaha.122.025295 · 2022 · External reference
Role of mitochondrial oxidative stress in glucose tolerance, insulin resistance, and cardiac diastolic dysfunction
10.1161/jaha.115.003046 · 2016 · External reference
TRPM7 kinase mediates hypomagnesemia-induced seizure-related death
10.1038/s41598-023-34789-2 · 2023 · External reference
Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction
10.1038/s41590-018-0272-2 · 2019 · External reference
Publisher correction: blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly
10.1038/s41590-020-0686-5 · 2020 · External reference
Human fetal ventricular cardiomyocyte, RL-14 cell line, is a promising model to study drug metabolizing enzymes and their associated arachidonic acid metabolites
10.1016/j.vascn.2014.11.005 · 2015 · External reference
Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits
10.1007/s00125-016-4134-x · 2017 · External reference
Dapagliflozin attenuates Na(+)/H(+) Exchanger-1 in cardiofibroblasts via AMPK activation
10.1007/s10557-018-6837-3 · 2018 · External reference
Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts
10.1093/cvr/cvz004 · 2019 · External reference
Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
10.1016/j.phrs.2020.104781 · 2020 · External reference
Crosstalk between sodium-glucose cotransporter inhibitors and sodium-hydrogen exchanger 1 and 3 in cardiometabolic diseases
10.3390/ijms222312677 · 2021 · External reference
Crucial role for sensory nerves and Na/H exchanger inhibition in dapagliflozin- and empagliflozin-induced arterial relaxation
10.1093/cvr/cvae156 · 2024 · External reference
Identification of TG100-115 as a new and potent TRPM7 kinase inhibitor, which suppresses breast cancer cell migration and invasion
10.1016/j.bbagen.2017.01.034 · 2017 · External reference
Suppression of TRPM7 enhances TRAIL-induced apoptosis in triple-negative breast cancer cells
10.1002/jcp.29820 · 2020 · External reference
Dapagliflozin in patients with heart failure and reduced ejection fraction
10.1056/nejmoa1911303 · 2019 · External reference
Inhibition of the sodium-proton antiporter (exchanger) is a plausible mechanism of potential benefit and harm for drugs designed to block sodium glucose co-transporter 2
10.31083/j.rcm.2018.02.021 · 2018 · External reference
Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?
10.1007/s10741-022-10220-2 · 2022 · External reference
Serum magnesium, outcomes, and the effect of empagliflozin in heart failure with mildly reduced and preserved ejection fraction: findings from EMPEROR-preserved
2026 · External reference
Serum magnesium and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-reduced
2026 · External reference
Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: a post hoc analysis of 10 randomized, placebo-controlled trials
10.1016/j.jdiacomp.2019.06.007 · 2019 · External reference
Activation of the Na(+)-H+ exchanger modulates angiotensin II-stimulated Na(+)-dependent Mg2+ transport in vascular smooth muscle cells in genetic hypertension
10.1161/01.hyp.34.3.442 · 1999 · External reference
Intracellular pH modulates cytosolic free magnesium in cultured chicken heart cells
10.1152/ajpcell.1992.262.4.c1024 · 1992 · External reference
Identification of a Mg2+-sensitive ORF in the 5'-leader of TRPM7 magnesium channel mRNA
10.1093/nar/gku951 · 2014 · External reference
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
10.1038/s41591-021-01536-x · 2021 · External reference
Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial
10.1161/circulationaha.123.065134 · 2023 · External reference
Dapagliflozin protects methamphetamine-induced cardiomyopathy by alleviating mitochondrial damage and reducing cardiac function decline in a mouse model
2022 · External reference
Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
10.1016/j.molmet.2022.101620 · 2022 · External reference
Empagliflozin improves diastolic function in HFpEF by restabilizing the mitochondrial respiratory chain
10.1161/circheartfailure.123.011107 · 2024 · External reference
Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway
10.1016/j.redox.2022.102288 · 2022 · External reference
Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation
10.1093/cvr/cvaa123 · 2020 · External reference
Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways
2020 · External reference
Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy
10.3389/fendo.2022.1011669 · 2022 · External reference
Canagliflozin prevents lipid accumulation, mitochondrial dysfunction, and Gut microbiota dysbiosis in mice with diabetic cardiovascular disease
2022 · External reference
Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients
10.3389/fphys.2018.01575 · 2018 · External reference
Na+/H+ exchangers of mammalian cells
10.1074/jbc.272.36.22373 · 1997 · External reference
Inhibition of the Na+-H+ exchanger with cariporide abolishes stretch-induced calcium but not sodium accumulation in mouse ventricular myocytes
10.1016/j.ceca.2004.06.006 · 2005 · External reference
The role of sodium-hydrogen ion exchange in patients undergoing coronary artery bypass grafting
10.1046/j.1540-8191.18.s1.4.x · 2003 · External reference
The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial
10.1016/s0735-1097(01)01608-4 · 2001 · External reference
Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute
10.1161/circulationaha.108.815944 · 2009 · External reference
Sex differences in heart failure with preserved ejection fraction
10.1161/jaha.120.018574 · 2021 · External reference
Progression of left ventricular diastolic dysfunction and risk of heart failure
10.1001/jama.2011.1201 · ExternalCitation · doi-reference
Suppression of TRPM7 enhances TRAIL-induced apoptosis in triple-negative breast cancer cells
10.1002/jcp.29820 · ExternalCitation · doi-reference
Empagliflozin, a sodium-glucose cotransporter inhibitor enhancing mitochondrial action and cardioprotection in metabolic syndrome
10.1002/jcp.31264 · ExternalCitation · doi-reference
Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials
10.1007/s00125-016-4101-6 · ExternalCitation · doi-reference
Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits
10.1007/s00125-016-4134-x · ExternalCitation · doi-reference
Magnesium deficiency: effect on bone and mineral metabolism in the mouse
10.1007/s00223-001-1091-1 · ExternalCitation · doi-reference
Expression profiling and immunolocalization of Na(+)-D-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats
10.1007/s00424-017-2056-1 · ExternalCitation · doi-reference
Dapagliflozin attenuates Na(+)/H(+) Exchanger-1 in cardiofibroblasts via AMPK activation
10.1007/s10557-018-6837-3 · ExternalCitation · doi-reference
Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence?
10.1007/s10741-022-10220-2 · ExternalCitation · doi-reference
Progression of left ventricular diastolic dysfunction in ethnic minorities
10.1007/s40292-013-0031-2 · ExternalCitation · doi-reference
Identification of TG100-115 as a new and potent TRPM7 kinase inhibitor, which suppresses breast cancer cell migration and invasion
10.1016/j.bbagen.2017.01.034 · ExternalCitation · doi-reference
TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway
10.1016/j.canlet.2013.01.031 · ExternalCitation · doi-reference
HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the heart failure Society of America
10.1016/j.cardfail.2024.07.001 · ExternalCitation · doi-reference
Inhibition of the Na+-H+ exchanger with cariporide abolishes stretch-induced calcium but not sodium accumulation in mouse ventricular myocytes
10.1016/j.ceca.2004.06.006 · ExternalCitation · doi-reference
The TRPM7 chanzyme is cleaved to release a chromatin-modifying kinase
10.1016/j.cell.2014.03.046 · ExternalCitation · doi-reference
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
10.1016/j.freeradbiomed.2024.01.015 · ExternalCitation · doi-reference
Inflammatory macrophage interleukin-1β mediates high fat diet induced heart failure with preserved ejection fraction
10.1016/j.jacbts.2022.08.003 · ExternalCitation · doi-reference
Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry
10.1016/j.jacc.2007.04.064 · ExternalCitation · doi-reference
Beyond adiposity: embracing complexity in diabetes-associated HFpEF
10.1016/j.jacc.2025.08.005 · ExternalCitation · doi-reference
Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: a post hoc analysis of 10 randomized, placebo-controlled trials
10.1016/j.jdiacomp.2019.06.007 · ExternalCitation · doi-reference
Pathophysiology of systolic and diastolic heart failure
10.1016/j.mcna.2012.07.001 · ExternalCitation · doi-reference
Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice
10.1016/j.metabol.2020.154324 · ExternalCitation · doi-reference
Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
10.1016/j.molmet.2022.101620 · ExternalCitation · doi-reference
Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
10.1016/j.phrs.2020.104781 · ExternalCitation · doi-reference
Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway
10.1016/j.redox.2022.102288 · ExternalCitation · doi-reference
Human fetal ventricular cardiomyocyte, RL-14 cell line, is a promising model to study drug metabolizing enzymes and their associated arachidonic acid metabolites
10.1016/j.vascn.2014.11.005 · ExternalCitation · doi-reference
SGLT2 inhibitors in management of severe hypomagnesemia in patients without diabetes: a report of 4 cases
10.1016/j.xkme.2023.100697 · ExternalCitation · doi-reference
Mitochondrial dysfunction causing cardiac sodium channel downregulation in cardiomyopathy
10.1016/j.yjmcc.2012.10.011 · ExternalCitation · doi-reference
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial
10.1016/s0140-6736(03)14285-7 · ExternalCitation · doi-reference
The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial
10.1016/s0735-1097(01)01608-4 · ExternalCitation · doi-reference
Diastolic heart failure: mechanisms and controversies
10.1038/ncpcardio1245 · ExternalCitation · doi-reference
TRPM7 kinase-mediated immunomodulation in macrophage plays a central role in magnesium ion-induced bone regeneration
10.1038/s41467-021-23005-2 · ExternalCitation · doi-reference
Self-renewing resident cardiac macrophages limit adverse remodeling following myocardial infarction
10.1038/s41590-018-0272-2 · ExternalCitation · doi-reference
Publisher correction: blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly
10.1038/s41590-020-0686-5 · ExternalCitation · doi-reference
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
10.1038/s41591-021-01536-x · ExternalCitation · doi-reference
TRPM7 kinase mediates hypomagnesemia-induced seizure-related death
10.1038/s41598-023-34789-2 · ExternalCitation · doi-reference
Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure
10.1038/s41598-025-93144-9 · ExternalCitation · doi-reference
Elucidating the role of the TRPM7 alpha-kinase: TRPM7 kinase inactivation leads to magnesium deprivation resistance phenotype in mice
10.1038/srep07599 · ExternalCitation · doi-reference
The role of sodium-hydrogen ion exchange in patients undergoing coronary artery bypass grafting
10.1046/j.1540-8191.18.s1.4.x · ExternalCitation · doi-reference
Trends in prevalence and outcome of heart failure with preserved ejection fraction
10.1056/nejmoa052256 · ExternalCitation · doi-reference
Dapagliflozin in patients with heart failure and reduced ejection fraction
10.1056/nejmoa1911303 · ExternalCitation · doi-reference
Empagliflozin in heart failure with a preserved ejection fraction
10.1056/nejmoa2107038 · ExternalCitation · doi-reference
Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction
10.1056/nejmoa2206286 · ExternalCitation · doi-reference
Semaglutide in patients with heart failure with preserved ejection fraction and obesity
10.1056/nejmoa2306963 · ExternalCitation · doi-reference
Ion channel-kinase TRPM7 is required for maintaining cardiac automaticity
10.1073/pnas.1311865110 · ExternalCitation · doi-reference
Na+/H+ exchangers of mammalian cells
10.1074/jbc.272.36.22373 · ExternalCitation · doi-reference
Characterization of the protein kinase activity of TRPM7/ChaK1, a protein kinase fused to the transient receptor potential ion channel
10.1074/jbc.m308820200 · ExternalCitation · doi-reference
Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction
10.1080/14779072.2018.1497485 · ExternalCitation · doi-reference
Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation
10.1093/cvr/cvaa123 · ExternalCitation · doi-reference
Crucial role for sensory nerves and Na/H exchanger inhibition in dapagliflozin- and empagliflozin-induced arterial relaxation
10.1093/cvr/cvae156 · ExternalCitation · doi-reference
Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts
10.1093/cvr/cvz004 · ExternalCitation · doi-reference
Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics
10.1093/jmcb/mjac028 · ExternalCitation · doi-reference
Identification of a Mg2+-sensitive ORF in the 5'-leader of TRPM7 magnesium channel mRNA
10.1093/nar/gku951 · ExternalCitation · doi-reference
Clinical significance of serum magnesium levels in patients with heart failure with preserved ejection fraction
10.1097/md.0000000000017069 · ExternalCitation · doi-reference
The TRPM7 channel kinase regulates store-operated calcium entry
10.1113/jp274006 · ExternalCitation · doi-reference
Intracellular pH modulates cytosolic free magnesium in cultured chicken heart cells
10.1152/ajpcell.1992.262.4.c1024 · ExternalCitation · doi-reference
Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension
10.1152/ajpheart.00903.2007 · ExternalCitation · doi-reference
The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE(-/-) mice
10.1155/2016/6305735 · ExternalCitation · doi-reference
Alteration of the transcriptional profile of human embryonic kidney cells by transient overexpression of mouse TRPM7 channels
10.1159/000327958 · ExternalCitation · doi-reference
Cariporide (HOE642), a selective Na+-H+ exchange inhibitor, inhibits the mitochondrial death pathway
10.1161/01.cir.0000093277.20968.c7 · ExternalCitation · doi-reference
Activation of the Na(+)-H+ exchanger modulates angiotensin II-stimulated Na(+)-dependent Mg2+ transport in vascular smooth muscle cells in genetic hypertension
10.1161/01.hyp.34.3.442 · ExternalCitation · doi-reference
2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association
10.1161/cir.0000000000001209 · ExternalCitation · doi-reference
Empagliflozin improves diastolic function in HFpEF by restabilizing the mitochondrial respiratory chain
10.1161/circheartfailure.123.011107 · ExternalCitation · doi-reference
10.1161/circulationaha.107.188965
10.1161/circulationaha.107.188965 · ExternalCitation · doi-reference
Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute
10.1161/circulationaha.108.815944 · ExternalCitation · doi-reference
Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum
10.1161/circulationaha.110.954388 · ExternalCitation · doi-reference
Impact of progression of diastolic dysfunction on mortality in patients with normal ejection fraction
10.1161/circulationaha.111.066423 · ExternalCitation · doi-reference
Timing of myocardial trpm7 deletion during cardiogenesis variably disrupts adult ventricular function, conduction, and repolarization
10.1161/circulationaha.112.000768 · ExternalCitation · doi-reference
Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial
10.1161/circulationaha.123.065134 · ExternalCitation · doi-reference
Magnesium supplementation attenuates pulmonary hypertension via regulation of magnesium transporters
10.1161/hypertensionaha.120.14909 · ExternalCitation · doi-reference
Role of mitochondrial oxidative stress in glucose tolerance, insulin resistance, and cardiac diastolic dysfunction
10.1161/jaha.115.003046 · ExternalCitation · doi-reference
Sex differences in heart failure with preserved ejection fraction
10.1161/jaha.120.018574 · ExternalCitation · doi-reference
Magnesium deficiency causes a reversible, metabolic, diastolic cardiomyopathy
10.1161/jaha.120.020205 · ExternalCitation · doi-reference
Circulating S-glutathionylated cMyBP-C as a biomarker for cardiac diastolic dysfunction
10.1161/jaha.122.025295 · ExternalCitation · doi-reference
Magnesium supplementation improves diabetic mitochondrial and cardiac diastolic function
10.1172/jci.insight.123182 · ExternalCitation · doi-reference
A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
10.1186/s12933-018-0790-0 · ExternalCitation · doi-reference
Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice
10.1371/journal.pone.0100777 · ExternalCitation · doi-reference
Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells
10.1371/journal.pone.0247234 · ExternalCitation · doi-reference
Inhibition of the sodium-proton antiporter (exchanger) is a plausible mechanism of potential benefit and harm for drugs designed to block sodium glucose co-transporter 2
10.31083/j.rcm.2018.02.021 · ExternalCitation · doi-reference
Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy
10.3389/fendo.2022.1011669 · ExternalCitation · doi-reference
Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients
10.3389/fphys.2018.01575 · ExternalCitation · doi-reference
Crosstalk between sodium-glucose cotransporter inhibitors and sodium-hydrogen exchanger 1 and 3 in cardiometabolic diseases
10.3390/ijms222312677 · ExternalCitation · doi-reference
Rosmarinic acid, as an NHE1 activator, decreases skin surface pH and improves the skin barrier function
10.3390/ijms23073910 · ExternalCitation · doi-reference
Comparative effects of sodium-glucose cotransporter 2 inhibitors on serum electrolyte levels in patients with type 2 diabetes: a pairwise and network meta-analysis of randomized controlled trials
10.34067/kid.0006672021 · ExternalCitation · doi-reference
